Cart
sales@molnova.com
Linzagolix
CAS No. 935283-04-8
Linzagolix( —— )
Catalog No. M27897 CAS No. 935283-04-8
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 89 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 431 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinzagolix
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
-
DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number935283-04-8
-
Formula Weight508.42
-
Molecular FormulaC22H15F3N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (245.86 mM)
-
SMILESCOc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Trujillo C, Goya P, Rozas I. Study of Meldrum's Acid Cyclization Reactions. J Phys Chem A. 2018 Mar 8;122(9):2535-2541.
molnova catalog
related products
-
Rel-TREM2 agonist-2
rel-5-(4-Chloro-2-fluorophenyl)-2,3-dimethyl-7-[(2R,4S)-tetrahydro-2-(1-methyl-1H-pyrazol-4-yl)-2H-pyran-4-yl]pyrido[3,4-b] The EC50 value of pyrazine against TREM2 was ≤ 0.05 μM and the E.max value was > 250 μM.
-
Cl-C6-PEG4-O-CH2COOH
Cl-C6-PEG4-O-CH2COOH (PROTAC Linker 4) is an efficient pegylated PROTAC linker commonly used in the synthesis of chloroanes (HaloPROTACs).
-
EURYCOMANONE
Eurycomanone is cytotoxic on HepG2 cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2.
